U.K. to keep PSE meds BTC
This article was originally published in The Tan Sheet
Restrictions on sales of drugs containing ephedrine and pseudoephedrine in the U.K. have proven effective in decreasing illicit methylamphetamine production, so the Medicines and Healthcare products Regulatory Agency will not shift the products to prescription only status. In August 2007, an agency advisory panel recommended ephedrine and PSE products be sold in packages no larger than 720 mg and its Commission on Human Medicines recommended limiting sales of the drugs to pharmacy only and to one package per person (1"The Tan Sheet" Jan. 14, 2008). MHRA said July 29 in wake of the changes, meth abuse has been contained and pharmacies have seen a 25 percent drop in PSE purchases. An executive said the agency will continue to monitor sales of the meth precursors
You may also be interested in...
A U.K. advisory panel determines behind-the-counter sales of nonprescription products containing epehedrine or pseudoephedrine effectively mitigate misuse of the drugs. The Medicines and Healthcare products Regulatory Agency's Commission on Human Medicines concluded in July that regulatory measures are "successful" and recommends maintenance of existing pharmacist monitoring and education programs. The report follows MHRA's July 2009 decision to not make precursors of methamphetamine prescription-only (1"The Tan Sheet" Aug. 3, 2009, In Brief)
U.K. drug firms say the country's regulatory agency is not allowing enough time to comply with an order banning nonprescription access to product packages with more than 720 mg of pseudoephedrine beginning April 1
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.